Seattle Genetics Highlights Data for Adcetris plus CHP in PTCL Patients

The biopharmaceutical is highlighting data it will present at the European Society for Medical Oncology Congress this weekend in Madrid.

Seattle Genetics will present data constituting an updated two-year durability analysis from a phase I trial testing its antibody drug conjugate Adcetris along with combination chemotherapy in patients with newly diagnosed, CD30 positive, peripheral T-cell lymphoma (PTCL).

In the trial patients received Adcetris coupled with what is considered standard treatment for PTCL, notably, either the CHOP chemotherapy regimen (A+CHOP), or CHP (A+CHP, CHOP minus vincristine).

Since PTCL is such a broad category, there was bound to be variations in the recruited patients, and indeed among the 26 patients:

• Nineteen have systemtic anaplastic large cell lymphoma (sALCL)
• Of those nineteen, sixteen have ALK-negative disease, associated with significantly poorer prognoses
• Seven patients with other unnamed types of PTCL

So the updated findings include the following, based on a median observation time of 27.1 months and involving those receiving A+CHP:

• Estimated 2 year progression-free survival rate is 54 percent; no progression events to report since they first reported data on this trial at the ASH meeting about ten months ago
• Estimated 2 year overall survival rate is 80 percent
• Common side effects, occurring in over 40 percent of patients: peripheral sensory neuropathy, nausea, fatigue, hair loss, diarrhea, shortness of breath

Seattle Genetics has already begun recruiting for a pivotal phase III randomized, double-blind, placebo-controlled trial pitting A+CHP against CHOP as front-line treatment in this patient population.

Source: Seattle Genetics